An Open-label Phase 1/2A Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TRC253, an Androgen Receptor Antagonist, in Patients With Metastatic Castration-resistant Prostate Cancer

Trial Profile

An Open-label Phase 1/2A Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TRC253, an Androgen Receptor Antagonist, in Patients With Metastatic Castration-resistant Prostate Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs TRC 253 (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors TRACON Pharmaceuticals
  • Most Recent Events

    • 08 Aug 2017 According to a TRACON Pharmaceuticals media release, dose escalation portion is expected to complete by the end of this year 2017.
    • 10 Jun 2017 Biomarkers information updated
    • 10 May 2017 According to a TRACON Pharmaceuticals media release, the company expected to start dosing in this trial in the second quarter of 2017. Dose escalation expected to complete in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top